The stock performance of Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) saw a notable uptick last week. Shares rose 8.14% during the regular session, closing at $3.19, and then 6.58% in after-hours trading to $3.40 on Friday. Notable advancements in the business’s revenue-generation tactics served as the catalyst for the rise.
Strategic Alliances to Promote Development
Recently, Cyclerion revealed plans to use its soluble guanylate cyclase (sGC) stimulator assets to help the business enter its next stage of expansion. The corporation intends to use these legacy assets to accomplish its strategic ambitions and create short-term income without immediately diluting shareholder ownership.
This development is demonstrated by a revised contract with Akebia Therapeutics. Under the revised terms, Cyclerion will receive $1.75 million in upfront and near-term payments, while Akebia assumes responsibility for intellectual property (IP) expenses for praliciguat beginning Q2 2025.
CYCN had already received $3 million upfront in 2021 from Akebia as part of the original deal and remains eligible for up to $560 million in potential milestone payments. Notably, the amended agreement includes higher, tiered sales-based royalties ranging from mid-single digits to 20%.
New Licensing Opportunities for Olinciguat
In addition, Cyclerion has signed an exclusive license option agreement for olinciguat, a vascular sGC stimulator, with CVCO Therapeutics, Inc. CVCO, a clinical-stage company specializing in microvascular dysfunction therapies, now has the exclusive right to evaluate olinciguat during the option period. During this time, CVCO assumes all ongoing IP-related expenses tied to the asset.
Building a Foundation for CNS Innovation
Cyclerion’s recent agreements underscore its strategy to maximize the value of its legacy assets while reallocating resources to acquire and develop new assets. These efforts, coupled with reduced operating expenses, enable the company to focus capital on building a robust pipeline in the central nervous system (CNS) therapeutic space.
Cyclerion is also exploring advanced-stage evaluations of promising assets, which could serve as the foundation for its future growth. CYCN remains committed to raising additional capital as required to support its plans, aiming to deliver long-term value for both shareholders and patients.
